KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Cash Flow (2016 - 2025)

CRISPR Therapeutics AG's Net Cash Flow history spans 11 years, with the latest figure at $61.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 15.98% year-over-year to $61.1 million; the TTM value through Dec 2025 reached $49.2 million, up 153.91%, while the annual FY2025 figure was $49.2 million, 153.91% up from the prior year.
  • Net Cash Flow for Q4 2025 was $61.1 million at CRISPR Therapeutics AG, down from $92.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $521.8 million in Q2 2021 and bottomed at -$636.3 million in Q3 2021.
  • The 5-year median for Net Cash Flow is -$42.1 million (2021), against an average of -$41.3 million.
  • The largest annual shift saw Net Cash Flow tumbled 695.46% in 2021 before it surged 3243.38% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$88.5 million in 2021, then tumbled by 223.76% to -$286.4 million in 2022, then surged by 51.61% to -$138.6 million in 2023, then surged by 152.44% to $72.7 million in 2024, then decreased by 15.98% to $61.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Net Cash Flow are $61.1 million (Q4 2025), $92.9 million (Q3 2025), and -$41.6 million (Q2 2025).